{"id":"https://openalex.org/W7902152","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps206","title":"Phase II study of irinotecan plus panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma (EAC).","display_name":"Phase II study of irinotecan plus panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma (EAC).","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W7902152","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps206","mag":"7902152"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.tps206","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps206","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps206","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"A. Atasoy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Atasoy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009471318","display_name":"Hye\u2010Jung Yoon","orcid":"https://orcid.org/0000-0002-3534-3295","observed_orcids":["https://orcid.org/0000-0002-3534-3295"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Yoon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022139249","display_name":"Ann Marie Egloff","orcid":"https://orcid.org/0000-0002-1182-2793","observed_orcids":["https://orcid.org/0000-0002-1182-2793"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. M. Egloff","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086074491","display_name":"Robert Louis Ferris","orcid":"https://orcid.org/0000-0001-6605-2071","observed_orcids":["https://orcid.org/0000-0001-6605-2071"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. L. Ferris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111559655","display_name":"A. Zaidi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. H. Zaidi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082047985","display_name":"Bruce Hough","orcid":"https://orcid.org/0009-0002-6238-1120","observed_orcids":["https://orcid.org/0009-0002-6238-1120"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Hough","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034392417","display_name":"Arlene A. Forastiere","orcid":"https://orcid.org/0000-0003-2238-3682","observed_orcids":["https://orcid.org/0000-0003-2238-3682"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. A. Forastiere","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111546490","display_name":"Blair Anderson Jobe","orcid":"https://orcid.org/0000-0001-6550-5315","observed_orcids":["https://orcid.org/0000-0001-6550-5315"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. A. Jobe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027622390","display_name":"Katie Sue Nason","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. S. Nason","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5005651831","display_name":"Michael K. Gibson","orcid":"https://orcid.org/0000-0002-1500-9281","observed_orcids":["https://orcid.org/0000-0002-1500-9281"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. K. Gibson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"TPS206","last_page":"TPS206"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10619","display_name":"Esophageal Cancer Research and Treatment","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10619","display_name":"Esophageal Cancer Research and Treatment","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.00839999970048666,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/esophageal-adenocarcinoma","display_name":"esophageal adenocarcinoma","score":0.9509999752044678},{"id":"https://openalex.org/keywords/panitumumab","display_name":"panitumumab","score":0.9330000281333923},{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":0.9990000128746033},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.8119999766349792},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.6690000295639038},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9449999928474426},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.6639999747276306},{"id":"https://openalex.org/keywords/fc-gamma-receptor","display_name":"Fc gamma receptor","score":0.7599999904632568},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.7850000262260437},{"id":"https://openalex.org/keywords/pharmacogenomics","display_name":"pharmacogenomics","score":0.7760000228881836},{"id":"https://openalex.org/keywords/kras-mutation","display_name":"KRAS mutation","score":0.9399999976158142},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6700000166893005},{"id":"https://openalex.org/keywords/overall-response","display_name":"overall response","score":0.4399999976158142},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6570000052452087},{"id":"https://openalex.org/keywords/patient-selection","display_name":"patient selection","score":0.5270000100135803},{"id":"https://openalex.org/keywords/simon-s-two-stage-design","display_name":"Simon two-stage design","score":0.5440000295639038}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8969689607620239},{"id":"https://openalex.org/C2778332735","wikidata":"https://www.wikidata.org/wiki/Q417775","display_name":"Panitumumab","level":5,"score":0.8686856627464294},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.8113085627555847},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.7313869595527649},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6613436341285706},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6340460181236267},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.598766565322876},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.5442987680435181},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.49157223105430603},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.4809112548828125},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.43862152099609375},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4373597204685211},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4353001117706299},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.42581647634506226},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4210033416748047},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3644271790981293},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.317193865776062}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.tps206","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps206","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps206","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.7900000214576721}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2080959432","https://openalex.org/W2804194728","https://openalex.org/W2611531664","https://openalex.org/W2101076600","https://openalex.org/W2602275689","https://openalex.org/W2263190204","https://openalex.org/W3123930579","https://openalex.org/W2521141758","https://openalex.org/W2590773246","https://openalex.org/W3010581980"],"abstract_inverted_index":{"TPS206":[0],"Background:":[1],"Esophageal":[2],"carcinoma":[3],"is":[4,10,37,55,67,107,335,351],"highly":[5],"lethal":[6],"and":[7,125,146,153,180,206,222,249,255,291,303,305,317,340,346],"the":[8,13,23,79,219,223,234,257,268,274,325,330],"incidence":[9],"increasing,":[11],"especially":[12],"subtype":[14],"of":[15,22,60,81,93,132,155,163,188,204,211,239,260,270,297,328,332],"EAC.":[16,34,102],"Our":[17,73],"group":[18,74],"demonstrated":[19],"that":[20],"overexpression":[21],"epidermal":[24],"growth":[25],"factor":[26],"receptor":[27],"(EGFR)":[28],"correlates":[29],"with":[30,52,129,139,324],"lower":[31],"survival":[32],"in":[33,69,218,359],"Panitumumab":[35],"(P)":[36],"a":[38,130,161,207,237],"high":[39],"affinity":[40],"fully":[41],"human":[42,48],"IgG2":[43],"monoclonal":[44],"antibody":[45],"directed":[46],"against":[47],"EGFR.":[49],"Cetuximab":[50],"combined":[51],"irinotecan":[53],"(I)":[54],"effective":[56],"for":[57,78,100,267,288,356],"second-line":[58,98],"treatment":[59,135],"advanced":[61,101],"colorectal":[62],"cancer":[63],"(CRC).":[64],"P":[65,94,140],"alone":[66],"active":[68],"EGFR":[70,298],"expressing":[71],"CRC.":[72],"has":[75],"empiric":[76],"evidence":[77],"activity":[80],"cetuximab":[82],"+":[83,95],"I.":[84],"As":[85],"such,":[86],"we":[87],"composed":[88],"this":[89,333],"phase":[90],"II":[91],"study":[92,312,344],"I":[96,147,175,209],"as":[97,111],"therapy":[99],"Methods:":[103],"The":[104,311,349],"primary":[105,326],"endpoint":[106,327],"overall":[108,122],"response":[109],"(OR)":[110],"measured":[112],"by":[113,295,306],"RECIST":[114],"(imaging":[115],"every":[116],"2":[117,229],"cycles).":[118],"Secondary":[119],"endpoints":[120],"include":[121,168,186],"survival,":[123],"safety/toxicity":[124],"correlative":[126],"studies.":[127],"Patients":[128],"history":[131],"one":[133],"prior":[134,174,192],"will":[136,215,225,242,251,264,285],"be":[137,216,226,243,252,265,286],"treated":[138],"9":[141],"mg/m2":[142,149],"on":[143,150,273],"day":[144,158],"1":[145,152],"125":[148],"days":[151],"8":[154],"each":[156],"21":[157],"cycle":[159,261],"to":[160,279,336,343,352],"maximum":[162],"6":[164],"cycles.":[165],"Inclusion":[166],"criteria":[167,185],"confirmed":[169],"EAC,":[170],"measurable":[171],"disease,":[172],"no":[173],"or":[176,230,365,369],"P,":[177],"PS":[178],"<2":[179],"normal":[181],"organ":[182],"function.":[183],"Exclusion":[184],"use":[187],"CYP":[189],"3A4":[190],"inhibitors,":[191],"anti-EGFR":[193],"therapy,":[194],"uncontrolled":[195],"intercurrent":[196],"illness.":[197],"A":[198],"Simon":[199],"two-stage":[200],"design":[201],"uses":[202],"power":[203],"80%":[205],"type":[208],"error":[210],"0.05.":[212],"18":[213],"patients":[214,241,319],"tested":[217],"first":[220],"stage,":[221,236],"trial":[224,334],"terminated":[227],"if":[228],"fewer":[231],"respond.":[232],"In":[233],"second":[235],"total":[238],"43":[240],"studied.":[244],"Correlative":[245],"Studies:":[246],"Research":[247,375],"blood":[248,341],"tissue":[250],"obtained":[253],"pre-treatment":[254],"during":[256],"third":[258],"week":[259],"2.":[262],"Blood":[263],"studied":[266],"role":[269],"FcgR":[271],"receptors":[272],"effector":[275],"cell":[276],"surface":[277],"leading":[278],"antibody-directed":[280],"cellular":[281],"cytotoxicity.":[282],"Tumor":[283],"tissues":[284],"analyzed":[287],"pharmacodynamic":[289],"(PD)":[290],"pharmacogenomic":[292],"(PG)":[293],"effects":[294],"measurement":[296],"pathway":[299],"components":[300],"using":[301],"FISH":[302],"IHC":[304],"kras":[307],"mutation":[308],"analysis.":[309],"Enrollment:":[310],"recently":[313],"opened":[314],"at":[315],"UPMC,":[316],"two":[318],"are":[320],"enrolled.":[321],"Significance:":[322],"Along":[323],"OR,":[329],"goal":[331,350],"utilize":[337],"sequential":[338],"tumor":[339],"sampling":[342],"PD":[345],"PG":[347],"correlates.":[348],"improve":[353],"patient":[354],"selection":[355],"targeted":[357],"therapies":[358],"future":[360],"trials.":[361],"Author":[362],"Disclosure":[363],"Employment":[364],"Leadership":[366],"Position":[367],"Consultant":[368],"Advisory":[370],"Role":[371],"Stock":[372],"Ownership":[373],"Honoraria":[374],"Funding":[376],"Expert":[377],"Testimony":[378],"Other":[379],"Remuneration":[380],"Amgen":[381]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}